KR920703003A - 혈관활성 바소토신 유도체 - Google Patents

혈관활성 바소토신 유도체

Info

Publication number
KR920703003A
KR920703003A KR1019920702039A KR920702039A KR920703003A KR 920703003 A KR920703003 A KR 920703003A KR 1019920702039 A KR1019920702039 A KR 1019920702039A KR 920702039 A KR920702039 A KR 920702039A KR 920703003 A KR920703003 A KR 920703003A
Authority
KR
South Korea
Prior art keywords
vasothocin
hgn
phe
derivative according
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019920702039A
Other languages
English (en)
Other versions
KR0171614B1 (ko
Inventor
칼요한 아우렐
페르 멜린
앤더스 닐슨
저지 트로이나르
Original Assignee
페링 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 페링 에이비 filed Critical 페링 에이비
Publication of KR920703003A publication Critical patent/KR920703003A/ko
Application granted granted Critical
Publication of KR0171614B1 publication Critical patent/KR0171614B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

내용 없음

Description

혈관활성 바소토신 유도체
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 다음과 같은 식을 가지는 바소토신 유도체.
    [이 식에서, Hmp=2-히드록시-3-메르캅토프로피온산 잔기Z=페닐알라닌(Phe) 또는 티노신(Try) Y=호모글루타민(Hgn) 또는 호모시툴린(Hci)Q=H 또는 1-3개의 아미노산 잔기로서 같거나 다른 천연 또는 비천연 L-또는 D-아미노산이며 n=1,2 또는 3이다.]
  2. 제1항에 있어서, Z=Phe, n=2이며 Q는 H인 것을 특징으로 하는 바소토신 유도체.
  3. 제1항에 있어서, Z=Phe, Y=Hgn, n=2이며 Q는 알라닐인 것을 특징으로 하는 비소토신 유도체.
  4. 제1항에 있어서, Z=Phe, Y=Hgn, n=2이며 Q는 L-2-아미노부티릴인것을 특징으로 하는 바소토신 유도체.
  5. 제1항에 있어서, Z=Phe, Y=Hci, n=2이며 Q는 H인 것을 특징으로 하는 바소토신 유도체.
  6. 제l항에 있어서, Z=Tyr, Y=Hgn, n=3이며 Q는 H인 것을 특징으로 하는 바소토신 유도체.
  7. 제1항에 있어서, Z=Tyr, Y=Hgn, n=2이며 Q는 H인 것을 특징으로 하는 바소토신 유도체.
  8. 활성성분으로서 1종이상의 제1항에 따르는 바소토신유도체와 함께 약제학적으로 허용 가능한 부가물 및/또는 희석제를 함유하는 것을 특징으로 하는 약제조성물.
  9. 제8항에 있어서, 비경구적 투여에 적합한 제제형태인 것을 특징으로 하는 약제조성물.
  10. 제9항에 있어서, 정맥내 투여에 적합한 용액의 형태인 것을 특징으로 하는 약제조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920702039A 1990-02-27 1991-02-26 혈관활성 바소토신 유도체 Expired - Fee Related KR0171614B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9000691.7 1990-02-27
SE9000691A SE502644C2 (sv) 1990-02-27 1990-02-27 Vasoaktiva vasotocinderivat
PCT/SE1991/000154 WO1991013092A1 (en) 1990-02-27 1991-02-26 Vasoactive vasotocin derivatives

Publications (2)

Publication Number Publication Date
KR920703003A true KR920703003A (ko) 1992-12-17
KR0171614B1 KR0171614B1 (ko) 1999-02-01

Family

ID=20378692

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920702039A Expired - Fee Related KR0171614B1 (ko) 1990-02-27 1991-02-26 혈관활성 바소토신 유도체

Country Status (19)

Country Link
US (1) US5459236A (ko)
EP (1) EP0517778B1 (ko)
JP (1) JP2957275B2 (ko)
KR (1) KR0171614B1 (ko)
AT (1) ATE137764T1 (ko)
AU (1) AU633198B2 (ko)
CA (1) CA2076749C (ko)
DE (1) DE69119409T2 (ko)
DK (1) DK0517778T3 (ko)
ES (1) ES2089196T3 (ko)
FI (1) FI109703B (ko)
HU (1) HU215121B (ko)
IE (1) IE62345B1 (ko)
IL (1) IL97298A (ko)
MC (1) MC2254A1 (ko)
NO (1) NO923333L (ko)
RU (1) RU2067586C1 (ko)
SE (1) SE502644C2 (ko)
WO (1) WO1991013092A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
PT710243E (pt) * 1993-06-29 2000-11-30 Ferring Bv Sintese melhorada de peptidos ciclicos.
JO2937B1 (en) * 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
KR101194586B1 (ko) * 2006-02-10 2012-10-25 훼링 비.브이. 신규 화합물
WO2009037586A2 (en) 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
RU2454426C1 (ru) * 2011-04-06 2012-06-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Пептид калий-уретический
KR101304427B1 (ko) 2011-04-12 2013-09-05 한국과학기술연구원 재사용이 용이한 기공체 - 위성 나노입자 복합체 및 그 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1246055A (en) * 1980-03-24 1988-12-06 Joseph H. Cort N-.omega.-substituted hormonogens of vasopressin and its synthetic analogs
SE469473B (sv) * 1987-10-07 1993-07-12 Ferring Ab Vasoaktiva peptider

Also Published As

Publication number Publication date
NO923333L (no) 1992-10-16
CA2076749C (en) 2001-02-20
JPH05504575A (ja) 1993-07-15
DE69119409D1 (de) 1996-06-13
RU2067586C1 (ru) 1996-10-10
WO1991013092A1 (en) 1991-09-05
EP0517778B1 (en) 1996-05-08
FI109703B (fi) 2002-09-30
SE9000691D0 (sv) 1990-02-27
SE9000691L (sv) 1991-08-28
IE62345B1 (en) 1995-01-25
HUT61580A (en) 1993-01-28
DE69119409T2 (de) 1996-09-05
SE502644C2 (sv) 1995-11-27
AU7342491A (en) 1991-09-18
US5459236A (en) 1995-10-17
EP0517778A1 (en) 1992-12-16
JP2957275B2 (ja) 1999-10-04
DK0517778T3 (da) 1996-08-19
IL97298A (en) 1995-08-31
ES2089196T3 (es) 1996-10-01
KR0171614B1 (ko) 1999-02-01
IE910648A1 (en) 1991-08-28
ATE137764T1 (de) 1996-05-15
AU633198B2 (en) 1993-01-21
CA2076749A1 (en) 1991-08-28
MC2254A1 (fr) 1993-03-25
FI923820L (fi) 1992-08-26
HU9202748D0 (en) 1992-12-28
NO923333D0 (no) 1992-08-26
FI923820A0 (fi) 1992-08-26
HU215121B (hu) 1998-09-28
IL97298A0 (en) 1992-05-25

Similar Documents

Publication Publication Date Title
EP0528312A3 (en) Cyclic peptides and use thereof
DE69002385D1 (de) Isolierung und strukturbestimmung des zytostatischen linearen depsipeptids dolastatin 15.
WO2000012542A3 (en) Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties
KR910000703A (ko) 테트라졸 자극성 아미노산 수용체의 길항물질
CA2215327A1 (en) Formulations for lipophilic compounds
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
CA2004991A1 (en) Deletion analogues of magainin peptides
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
KR900003163A (ko) 시클로헥산 유도체
KR940005669A (ko) 사이클로펩타이드, 및 점막에 적용시 흡수 촉진제로서의 이의 용도
KR920703003A (ko) 혈관활성 바소토신 유도체
CA2042972A1 (en) Treatment of ocular hypertension with a synergistic combination for ocular administration
ES2196187T3 (es) Conjugados peptidicos derivados de las hormonas timicas, su utilizacion a titulo de medicamento y composiciones que los contienen.
DE69808938D1 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen
KR930017885A (ko) 항종양 조성물 및 종양의 치료방법
MY103251A (en) Biologically active molecules
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
GR3001922T3 (en) Use of n,n'-bis-l-amino acid-l-cystin peptides in amino acid preparations for oral and parenteral administration
KR950010884A (ko) 사람 및 동물에서 염증성 반응을 일으키는 공격 또는 패혈증 치료용의 아미노산계 조성물
KR890009974A (ko) 신규 화합물들
NO901558L (no) Vasoaktive peptider.
KR870010080A (ko) 면역촉진 활성을 갖는 트리펩티드
KR970058720A (ko) 향균 및 항진균 활성을 갖는 펩타이드
SE8901660D0 (sv) Anvaendning av gonadoliberinderivat foer fram- staellning av tumoerinhiberande farmaceutiska kompositioner
SE9003040D0 (sv) Analogues of cyclolinopeptide a and the use thereof

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920826

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19951208

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19920826

Comment text: Patent Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19980720

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19981021

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19981021

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20011022

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20021015

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20021015

Start annual number: 5

End annual number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20040710